Kayla Sondria Freeman

Kayla Freeman practices at Emory University Hospital in Atlanta, Georgia, part of Emory University.

Kayla Freeman's NPI, 1891319091, was assigned on June 3, 2020. Kayla Freeman holds Georgia license RN264148.

Kayla Freeman's primary practice is Emory University Hospital, at 1364 Clifton Road, NE, Atlanta, GA 30322 in De Kalb County. The practice phone is (404) 686-8500.

Kayla Freeman's primary practice is Emory University Hospital in Atlanta, Georgia, part of Emory University. Kayla Freeman is also affiliated with Emory University Hospital Midtown. The medical group on file is Emory Clinic. Dmand AI also links Kayla Freeman to 3 more hospitals, 1 ambulatory surgery center and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Kayla Freeman practices, 6 sites in all. Vendor and product names are available with a free account.

Family is Kayla Freeman's primary specialty in the NPI Registry, under taxonomy code 363LF0000X. Kayla Freeman is licensed in Georgia.

CMS counts 121 Medicare patients who saw Kayla Freeman in 2024. The largest group is 65 to 74, with 68 patients. 75% of them have cancer, and 63% have high blood pressure. Their average risk score is 1.60, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Kayla Freeman's median patient age at 71, with 90% women.

In 2024, Kayla Freeman wrote 468 Medicare Part D claims for 165 patients. 92% of them were for generic drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Kayla Freeman for performance year 2024, reported through an alternative payment model (APM). Kayla Freeman accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Kayla Freeman as offering telehealth.

CMS Open Payments shows 8 general payments to Kayla Freeman from 5 drug and device companies in 2025. Consulting fees make up the largest share, 61% of the total. Stemline Therapeutics Inc. paid the most, $745.